---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-039308"
form_type: "8-K"
ticker: "SNWV"
cik: "0001417663"
company_name: "SANUWAVE Health, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:02:59.473443+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SANUWAVE Q2 revenue $4.7M (+20% YoY); net loss $7.3M; guides Q3 growth 15-25%

## Summary
- Q2 revenue $4.7M (+20% YoY) within 15-25% guidance; H1 revenue $8.5M (+19%).
- Gross margin improved to 74% from 72%; operating income $0.9M with $1.25M one-time expense reversal.
- Net loss $7.3M vs net income $1.6M in Q2 2022 due to non-cash derivative liability losses.
- Q3 2023 revenue growth guidance 15-25% YoY; inventory constraints expected to ease in Q4.
- Recent: CEO Morgan Frank (May), President Andrew Walko (July), $3M asset-backed notes issued.

## SEC filing metadata
- accession: 0001140361-23-039308
- form_type: 8-K
- ticker: SNWV
- cik: 0001417663
- company_name: SANUWAVE Health, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417663/000114036123039308/0001140361-23-039308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417663/000114036123039308/brhc20057422_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-039308
- JSON: https://secwatch.observer/filing/0001140361-23-039308.json
- Plain text: https://secwatch.observer/filing/0001140361-23-039308.txt

## Key facts
- Earnings Releases
  SANUWAVE Health, Inc. reported second quarter ended June 30, 2023 results: revenue $4.7 million, net income $7.3 million. Guidance reaffirmed.
  - Period: second quarter ended June 30, 2023
  - Revenue: $4.7 million
  - Net income: $7.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: wound care products, today announced its 2nd quarter 2023 results. For the three months ended June 30, 2023: ■ Revenue for the three months ended June 30, 2023 totaled $4.7 million, an increase of 20%, as compared to $3.9 million for the same period of 2022. This growth falls within the previously provided guidance range of 15-25% for Q2 2023. Revenue for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417663/000114036123039308/0001140361-23-039308-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.